A Study of Autologous Neo-Kidney Augment™ (NKA) in Type 2 Diabetics With Chronic Kidney Disease
Diabetes Mellitus - Type 2 | Diseases of the Kidney & Urinary Tract
What is the purpose of this trial?
The purpose of the present study is to compare the safety and efficacy of up to 2 injections of NKA given 3 to 6 months apart (maximum) in subjects who are randomized to receive their first treatment as soon as the NKA product is made available versus subjects who are randomized to undergo contemporaneous, standard-of-care treatment for CKD during the first 12 18 months prior to receiving up to 2 injections of NKA.
- Ages30 - 80 years
- Trial withinRegen
- Start Date06/10/2018
- End Date12/30/2018
- Last Updated06/13/2018
- Study HIC#2000021970